^
    2d
    CRIMSON-NE: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 45 | Trial completion date: May 2040 --> Mar 2041
    Enrollment closed • Enrollment change • Trial completion date
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide
    2d
    Primary Cutaneous CD4⁺ Small/Medium T-cell Lymphoproliferative Disorder With T-cell Receptor (TCR) Clonality: The Importance of Clinical Context in Management. (PubMed, Cureus)
    Given the lesion's location in a cosmetically sensitive area, care was coordinated with dermatology, hematology/oncology, and plastic surgery. This case highlights the importance of clinicopathologic correlation in distinguishing PCSM-TCLPD from its malignant mimickers and in guiding appropriate management.
    Journal
    |
    CD4 (CD4 Molecule)
    2d
    KPT-330-mediated XPO1 inhibition impairs homologous recombination and enhances radiosensitivity in extranodal NK/T-cell lymphoma. (PubMed, Br J Cancer)
    XPO1 inhibition impairs HR and enhances radiosensitivity by disrupting the c-Myc-RAD51/CHEK1 axis. These findings support prospective evaluation of KPT-330-based radiosensitization in R/R ENKTL.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • XPO1 (Exportin 1)
    |
    Xpovio (selinexor)
    2d
    Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=78, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | N=38 --> 78
    Enrollment open • Enrollment change
    |
    Imfinzi (durvalumab) • lenalidomide
    3d
    Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides (clinicaltrials.gov)
    P1, N=10, Suspended, University of Alabama at Birmingham | Trial completion date: Jul 2026 --> Jul 2027 | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)
    3d
    Adulthood diagnosis of Nijmegen breakage syndrome in twins with antibody deficiency clinical presentation. (PubMed, Clin Immunol)
    These findings expand the genotypic spectrum of NBS and demonstrate that compound heterozygosity for non-classical NBN variants can lead to an adult identification of the disease. These cases highlight the importance of integrating genetic and functional analyses to facilitate the recognition of DNA repair disorders beyond childhood and to guide appropriate clinical surveillance and management.
    Journal
    |
    NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin))
    6d
    RV-CL-PTCL-PI-003974: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed
    Trial completion
    |
    ALK negative
    |
    lenalidomide • romidepsin
    6d
    Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease. (PubMed, Cancer Treat Res Commun)
    BV is a key therapy for CD30-positive CTCL. While real-world experience suggests potential activity in CD30-negative or low disease, prospective trials are needed to define its role in this challenging subgroup.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    6d
    Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma (clinicaltrials.gov)
    P3, N=93, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    gemcitabine • romidepsin • Onureg (azacitidine oral)
    7d
    Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing. (PubMed, Front Oncol)
    Despite CHOP, CHOEP, DA-EPOCH, and AC-CHOP (azacitidine plus chidamide) regimens, the patient experienced primary refractory disease and died 6 months from diagnosis following COVID-19 superinfection. To our knowledge, this is the first case reporting single-cell transcriptomic comparison of skin versus blood compartments in PTCL-NOS, revealing how cutaneous microenvironment sculpts aggressive malignant phenotypes and providing potential targets for compartment-specific therapy.
    Journal
    |
    IL17A (Interleukin 17A)
    |
    azacitidine • Epidaza (chidamide)
    7d
    Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns. (PubMed, Haematologica)
    These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK negative